Patents by Inventor James G. Tarrant
James G. Tarrant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210171515Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: ApplicationFiled: February 19, 2021Publication date: June 10, 2021Inventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J.W.M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung
-
Patent number: 10414760Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: GrantFiled: November 29, 2016Date of Patent: September 17, 2019Assignee: ANGION BIOMEDICA CORP.Inventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J. W. M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung
-
Publication number: 20180148438Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: ApplicationFiled: November 29, 2016Publication date: May 31, 2018Applicant: Angion Biomedica CorpInventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J.W.M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung
-
Publication number: 20150158853Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: ApplicationFiled: September 23, 2014Publication date: June 11, 2015Applicant: ANGION BIOMEDICA CORPInventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J.W.M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung
-
Publication number: 20140329871Abstract: The present invention provides compounds having the general structural Formula (I): and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis or dysproliferation.Type: ApplicationFiled: December 2, 2012Publication date: November 6, 2014Applicant: ANGION BIOMEDICA CORP.Inventors: Rama K. Mishira, Bijoy Panicker, James G. Tarrant, Dong Sung Lim, Lambertus J.W.M. Oehlen, Dawoon Jung
-
Patent number: 8865752Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: GrantFiled: July 4, 2013Date of Patent: October 21, 2014Assignee: Angion Biomedica Corp.Inventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J. W. M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung
-
Publication number: 20140018401Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: ApplicationFiled: July 4, 2013Publication date: January 16, 2014Applicant: ANGION BIOMEDICA CORPInventors: Bijoy Panicker, Dong Sung Lim, Rama K. Mishra, Lambertus J.W.M. Oehlen, James G. Tarrant, Xiaokang Zhu, Dawoon Jung
-
Patent number: 8513291Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: GrantFiled: June 1, 2011Date of Patent: August 20, 2013Assignee: Angion Biomedica Corp.Inventors: Bijoy Panicker, Lambertus J. W. M. Oehlen, James G. Tarrant, Dong Sung Lim, Xiaokang Zhu, Dawoon Jung, Rama K. Mishra
-
Publication number: 20130102643Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.Type: ApplicationFiled: June 1, 2011Publication date: April 25, 2013Inventors: Bijoy Panicker, Lambertus J.W.M. Oehlen, James G. Tarrant, Dong Sung Lim, Xiaokang Zhu, Dawoon Jung, Rama K. Mishra
-
Patent number: 8378104Abstract: Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.Type: GrantFiled: February 11, 2011Date of Patent: February 19, 2013Assignee: OSI Pharmaceuticals, LLCInventors: Keith R. Hornberger, Dan M. Berger, Xin Chen, Andrew P. Crew, Hanqing Dong, Andrew Kleinberg, An-Hu Li, Lifu Ma, Mark J. Mulvihill, Bijoy Panicker, Kam W. Siu, Arno G. Steinig, James G. Tarrant, Jing Wang, Qinghua Weng, Rajaram Sangem, Ramesh C. Gupta
-
Publication number: 20120046267Abstract: Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.Type: ApplicationFiled: February 11, 2011Publication date: February 23, 2012Inventors: Keith R. Hornberger, Dan M. Berger, Xin Chen, Andrew P. Crew, Hanqing Dong, Andrew Kleinberg, An-Hu Li, Lifu Ma, Mark J. Mulvihill, Bijoy Panicker, Kam W. Siu, Arno G. Steinig, James G. Tarrant, Jing Wang, Qinghua Weng, Rajaram Sangem, Ramesh C. Gupta
-
Patent number: 7253168Abstract: Compounds of Formula I are provided, in which variables are as described herein: Such compounds may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).Type: GrantFiled: April 6, 2005Date of Patent: August 7, 2007Assignee: Neurogen CorporationInventors: Alan J. Hutchison, Bertrand L. Chenard, James G. Tarrant, Guiying Li, Manuka Ghosh, George P. Luke, John M. Peterson, Wallace C. Pringle, Mary-Margaret E. O'Donnell, Kyungae Lee, Linda M. Gustavson, Dario Doller
-
Patent number: 7223757Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.Type: GrantFiled: November 30, 2005Date of Patent: May 29, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
-
Patent number: 7081454Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.Type: GrantFiled: October 2, 2002Date of Patent: July 25, 2006Assignee: Bristol-Myers Squibb Co.Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
-
Patent number: 6916942Abstract: A process for the preparation of novel C-4 carbonate taxanes useful as antitumor agentsType: GrantFiled: April 19, 2004Date of Patent: July 12, 2005Assignee: Bristol-Myers Squibb CompanyInventors: John F. Kadow, Harold Mastalerz, Joydeep Kant, Qiufen May Xue, James G. Tarrant
-
Patent number: 6908916Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.Type: GrantFiled: November 14, 2002Date of Patent: June 21, 2005Assignee: Bristol Myers Squibb CompanyInventors: Harold Mastalerz, Guifen Zhang, James G. Tarrant, Gregory D. Vite
-
Publication number: 20040225009Abstract: A process for the preparation of novel C-4 carbonate taxanes useful as antitumor agents.Type: ApplicationFiled: April 19, 2004Publication date: November 11, 2004Inventors: John F. Kadow, Harold Mastalerz, Joydeep Kant, Qiufen May Xue, James G. Tarrant
-
Patent number: 6750246Abstract: The present invention concerns novel taxane derivatives, their use as antitumor agents, and pharmaceutical formulations. The invention claims compounds of formula I and the use of compounds of formula I or pharmaceutical salts thereof as oral drugs for the treatment of human or veterinary disease. in which: R is phenyl, isopropyl, or tert butyl; R1 is —C(O)Rz in which Rz is (CH3)3CO—, (CH3)3CCH2—, CH3(CH2)3O—, cyclobutyl-, cyclohexyloxy, or (2-furyl); R2 is CH3C(O)O—.Type: GrantFiled: November 14, 2000Date of Patent: June 15, 2004Assignee: Bristol-Myers Squibb CompanyInventors: John F. Kadow, Harold Mastalerz, Qiufen May Xue, Steven Hansel, Mary Edson Zoeckler, William C. Rose, James G. Tarrant
-
Publication number: 20040044203Abstract: The present invention provides compounds of formula I 1Type: ApplicationFiled: October 2, 2002Publication date: March 4, 2004Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
-
Publication number: 20030186983Abstract: The present invention provides compounds of formula I 1Type: ApplicationFiled: November 14, 2002Publication date: October 2, 2003Inventors: Harold Mastalerz, Guifen Zhang, James G. Tarrant, Gregory D. Vite
